Trial · NCT04576988
Adverse events484
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 484
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Thrombocytopenia | Blood and lymphatic system disorders | Sotatercept Plus Background PAH Therapy (DBPC Period) | 8 | 163 | 9 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Placebo Plus Background PAH Therapy (DBPC Period) | 3 | 160 | 3 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Sotatercept Plus Background PAH Therapy (LTDB Period) | 8 | 158 | 9 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Placebo Plus Background PAH Therapy (LTDB Period) | 0 | 142 | 0 |
| other | Diarrhoea | Gastrointestinal disorders | Sotatercept Plus Background PAH Therapy (DBPC Period) | 20 | 163 | 21 |
| other | Diarrhoea | Gastrointestinal disorders | Placebo Plus Background PAH Therapy (DBPC Period) | 12 | 160 | 13 |
| other | Diarrhoea | Gastrointestinal disorders | Sotatercept Plus Background PAH Therapy (LTDB Period) | 6 | 158 | 7 |
| other | Diarrhoea | Gastrointestinal disorders | Placebo Plus Background PAH Therapy (LTDB Period) | 3 | 142 | 4 |
| other | Nausea | Gastrointestinal disorders | Sotatercept Plus Background PAH Therapy (DBPC Period) | 17 | 163 | 25 |
| other | Nausea | Gastrointestinal disorders | Placebo Plus Background PAH Therapy (DBPC Period) | 17 | 160 | 26 |
| other | Nausea | Gastrointestinal disorders | Sotatercept Plus Background PAH Therapy (LTDB Period) | 8 | 158 | 11 |
| other | Nausea | Gastrointestinal disorders | Placebo Plus Background PAH Therapy (LTDB Period) | 3 | 142 | 5 |
| other | Fatigue | General disorders | Sotatercept Plus Background PAH Therapy (DBPC Period) | 17 | 163 | 20 |
| other | Fatigue | General disorders | Placebo Plus Background PAH Therapy (DBPC Period) | 12 | 160 | 12 |
| other | Fatigue | General disorders | Sotatercept Plus Background PAH Therapy (LTDB Period) | 10 | 158 | 12 |
| other | Fatigue | General disorders | Placebo Plus Background PAH Therapy (LTDB Period) | 4 | 142 | 4 |
| other | Injection site pain | General disorders | Sotatercept Plus Background PAH Therapy (DBPC Period) | 11 | 163 | 12 |
| other | Injection site pain | General disorders | Placebo Plus Background PAH Therapy (DBPC Period) | 10 | 160 | 12 |
| other | Injection site pain | General disorders | Sotatercept Plus Background PAH Therapy (LTDB Period) | 0 | 158 | 0 |
| other | Injection site pain | General disorders | Placebo Plus Background PAH Therapy (LTDB Period) | 1 | 142 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04576988/events